SCHEMBL4948667

SCHEMBL4948667

c1n[nH]c2c1CCCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.41
DAPK3 O43293 2/20 0.41
PRKACA P17612 2/20 0.41
LTK P29376 2/20 0.41
GRK5 P34947 2/20 0.41
MAP2K2 P36507 2/20 0.41
MAPK8 P45983 2/20 0.41
CSNK1A1 P48729 2/20 0.41
CDK8 P49336 2/20 0.41
CLK2 P49760 2/20 0.41
GSK3B P49841 2/20 0.41
CDK9 P50750 2/20 0.41
RPS6KA3 P51812 2/20 0.41
CDK5 Q00535 2/20 0.41
MAP2K1 Q02750 2/20 0.41
PTK2 Q05397 2/20 0.41
TYRO3 Q06418 2/20 0.41
ROCK1 Q13464 2/20 0.41
DYRK1A Q13627 2/20 0.41
NTRK3 Q16288 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31687184 1.00 KDR (0.41) KDRDAPK3PRKACALTKGRK5
SCHEMBL31496664 1.00 KDR (0.41) KDRDAPK3PRKACALTKGRK5
SCHEMBL29649189 1.00 KDR (0.41) KDRDAPK3PRKACALTKGRK5
SCHEMBL10509 0.98
Hydrochloric Acid SCHEMBL30066525 0.95 KDR (0.41) KDRDAPK3PRKACALTKGRK5
Hydrochloric Acid SCHEMBL30801293 0.95 KDR (0.41) KDRDAPK3PRKACALTKGRK5
SCHEMBL400139 0.93
Hydrazine SCHEMBL6036676 0.91 DRD4 (0.40) KDRDAPK3PRKACALTKGRK5
Oxalic Acid SCHEMBL572020 0.86 KDM4E (0.40) KDRDAPK3PRKACALTKGRK5
SCHEMBL30994991 0.81 TRIM24 (0.39) KDRDAPK3PRKACALTKGRK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3256450-B1 SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF MERCK SHARP & DOHME (US) 2020-12-02 EP disclosed
EP-3256450-B1 SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF MERCK SHARP & DOHME (US) 2020-12-02 EP disclosed
US-10221142-B2 Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof MERCK SHARP & DOHME CORP. (US) 2019-03-05 US disclosed
US-10221142-B2 Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof MERCK SHARP & DOHME CORP. (US) 2019-03-05 US disclosed
US-20180016239-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2018-01-18 US disclosed
US-20180016239-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2018-01-18 US disclosed
US-20180016239-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2018-01-18 US disclosed
EP-3256450-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF Merck Sharp & Dohme Corp. (US) 2017-12-20 EP disclosed
US-9776963-B2 Small molecule CD4 mimetics and uses thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-10-03 US disclosed
US-9776963-B2 Small molecule CD4 mimetics and uses thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-10-03 US disclosed
US-7241778-B2 Non-imidazole aryloxypiperidines ORTHO MCNEIL PHARMACEUTICAL, INC (US) 2007-07-10 US disclosed
US-7241778-B2 Non-imidazole aryloxypiperidines ORTHO MCNEIL PHARMACEUTICAL, INC (US) 2007-07-10 US disclosed
WO-2007053427-A2 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
US-20070072837-A1 Phenylalkynes APODACA RICHARD 2007-03-29 US disclosed
US-20070072837-A1 Phenylalkynes APODACA RICHARD 2007-03-29 US disclosed
US-7186732-B2 Non-imidazole aryloxyalkylamines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2007-03-06 US disclosed
US-7186732-B2 Non-imidazole aryloxyalkylamines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2007-03-06 US disclosed
EP-1311482-B1 NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS ORTHO MCNEIL PHARM INC (US) 2007-02-21 EP disclosed
WO-2006108488-A1 TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 WO disclosed
US-20060235013-A1 Tricyclic azole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016239-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF RORB, RORA, RORC KDR 4096/4885DAPK3 2335/4885PRKACA 385/4885
US-20070072837-A1 Phenylalkynes HRH2, HRH3, HNMT KDR 3835/4885DAPK3 4507/4885PRKACA 2792/4885
US-20060235013-A1 Tricyclic azole derivatives CYP3A5, CYP3A43, CYP11B1 KDR 3082/4885DAPK3 2234/4885PRKACA 1088/4885
US-10221142-B2 Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof RORB, RORA, RORC KDR 4096/4885DAPK3 2335/4885PRKACA 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.